RFL Rafael Holdings, Inc.
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C (NPC), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate. The company is also involved in developing Promitil, a pegylated liposomal mitomycin-C lipidic prodrug which is designed molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form. In addition, it develops surgical and procedural devices, including orthopedic arthroscopy instrument for carpal and cubital tunnel syndrome. Further, the company provides technological solutions specifically engineered for increased bioavailability of cannabinoids. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.…
Industry Peers
Real Estate ServicesKey Statistics
About Rafael Holdings (NYSE: RFL)
›
Rafael Holdings (NYSE: RFL) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Real Estate Services industry, part of the Real Estate sector, and reports about 15 employees.
The shares were at 0.9000 USD on 19 November 2026, down 26.2% over 52 weeks. Its 52-week range is 0.8500 USD to 3.960 USD: the price is 77.3% below the high and 5.9% above the low.
Its market capitalisation is 46.96M USD.
Rafael Holdings reports return on equity of -44.7% and revenue down 30.3% year over year.
It holds more cash than debt, a net cash position of 21.46M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 10 December 2026.